Colorectal carcinoma (CRC) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-IBD-CRC-PREVENTION-CHROMOENDOSCOPY`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-CRC`
Sources	`SRC-ESMO-COLON-2024` `SRC-ESMO-CRC-2024` `SRC-NCCN-COLON-2025`

Notes

STUB — v0.3 chronic-condition prevention pilot (IBD-associated CRC). Two-Co-Lead signoff queued. Mesalamine chemoprevention controversy noted in rationale; mixed RCT support — ECCO 2024 considers it reasonable add-on but not standard of care. Sources TODO: AGA Clinical Practice Update on Surveillance and Management of Dysplasia in IBD (Murthy 2021) and ECCO Guidelines on IBD (2024) as new SRC entities — primary citations for chromoendoscopy preference, dysplasia decision-tree, and PSC-IBD annual cadence.

Used By

Indication

IND-IBD-CRC-PREVENTION-OBSERVATION - IND-IBD-CRC-PREVENTION-OBSERVATION

Red flag

RF-IBD-CRC-PREVENTION - Long-standing inflammatory bowel disease (IBD) with colonic involvement — either ulcerati...